ALX Oncology (NASDAQ:ALXO – Get Free Report) released its earnings results on Monday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports.
ALX Oncology Price Performance
Shares of NASDAQ ALXO opened at $1.04 on Monday. The stock has a market cap of $143.81 million, a P/E ratio of -0.92 and a beta of 0.61. The firm has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.81. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. ALX Oncology has a 52-week low of $0.86 and a 52-week high of $2.66.
Analyst Ratings Changes
Several brokerages have commented on ALXO. Wall Street Zen cut shares of ALX Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings upgraded ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $4.75.
Get Our Latest Research Report on ALX Oncology
ALX Oncology Company Profile
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.
Read More
- Five stocks we like better than ALX Oncology
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
